Epilepsy community calls for urgent action to prevent Brexit-related epilepsy deaths
SUDEP Action and a coalition of epilepsy organisations and experts continue to call for urgent action to prevent Brexit-related epilepsy deaths following the release of Government’s Yellowhammer document.
The coalition recently called on Government to publish their No Deal Brexit 'Yellowhammer' papers, so steps can be taken to prevent epilepsy deaths due to medication shortages. The report has now been made public but has done little to reassure the concerned epilepsy community.
Read our updated statement expressing our concerns here:
Missed our campaigning earlier this week? Read more about what the Coalition called for below:
We called for transparency over No-Deal planning:
This latest call from the coalition follows revelations by Dr David Nicholl about patient safety concerns. We trust Dr Nicholl flagging these public interest concerns - as an expert doctor who has seen secret Government information and advice, and was involved in writing the secret YellowHammer report. In the light of this, and the recent attack on the integrity of Dr Nicholl, we called for the publication of the medicines sections of Yellowhammer, so that the record can be set straight and the public interest protected.
The Sunday Times published an article once again highlighting the significant risk Brexit is likely to have on people living with epilepsy, or other health conditions requiring regular medication. Since December 2018, SUDEP Action have led on this issue, campaigning with epilepsy/neurology organisations and experts, to express repeated concern over the lack of transparency over Government's Brexit planning to ensure life-saving epilepsy medication supplies are not disrupted, regardless of the Brexit outcome.
Despite our continued call for clarity, involving repeated letters to Government, including letters published in The Sunday Times, The Guardian, and also coverage by Channel4 News about the danger to life that ill-prepared medicine shortages could pose; we have still received no firm evidence that people with epilepsy will not be put at additional, life-threatening risk.
During the Parliamentary Debate on medicine shortages in March 2019, MPs were briefed on key issues, and SUDEP Action was also a key witness in a Judicial Review earlier this year, as well as inputting into two special meetings on Brexit and medicines with the All Party Parliamentary Groups on Epilepsy and the All Party Parliamentary Group on Medicines and Devices. However, Government has yet to meet with members of the coalition about this issue.
We wrote an open letter to Government sharing not only our concerns as experts in the field of epilepsy mortality, but the fears of our supporters, patients and members of the public who are increasingly in contact and worried about being able to access their epilepsy medications. This letter was also sent direct to the Prime Minister.
You can read our letter here:
Brexit Epilepsy Risks - Letter to Government (9th Sept 2019)
SUDEP Action has received an acknowledgement that our letter to the Prime Minister on 9th September which requested a meeting with him is under consideration. We await his response.
“We are now horrified by the prospect of a No Deal Brexit, that will inevitably lead to an increasing of risk for people with epilepsy. Some doctors and nurses, and patients, are already struggling to get hold of medicines, and a No Deal Brexit can only will make this worse. Access to a continuous supply of medicine, tailored by a specialist to what works for that particular patient, is the first line of defence against unnecessary epilepsy deaths. We predict rising deaths with any rising of risks.
There is still a potential threat of a No Deal Brexit, despite best efforts of some to prevent this. We understand that the civil service is working hard to avoid any current shortages. In light of this, we struggle to understand why politicians would gamble with people’s lives by allowing a No Deal to happen. People with epilepsy are already at an increased risk of premature death. Medicine supply issues, changes to their treatment routines and increased stress and anxiety, could make these risks life threatening. We worry hugely that politicians will not ever know whether any avoidable deaths have followed a medicines shortage, as we understand there is no dedicated system for reporting of these deaths“
Jane Hanna OBE, CEO SUDEP Action
What you can do
If you have epilepsy, know someone living with the condition, or are a clinician who supports those with epilepsy and are concerned about what this means for you - please see our Medication Shortages and Managing Risks page.
It is vital that people with epilepsy do not stop taking or make changes to their medication without speaking to the clinician who originally prescribed their medication. If you have concerns over this, please speak to the clinician who helps to manage your epilepsy. These epilepsy helplines may also be able to provide you with advice.
SUDEP Action strives to help highlight and prevent the 21 deaths a week in the UK from epilepsy. The national charity represents a community of bereaved families, supported by a network of health professionals, researchers and industry specialists.
Disclaimer: The views expressed on this webpage are those of SUDEP Action and do not necessarily represent the views of all those in the Epilepsy Coalition or those who have signed up to the letter.